Study To Optimize Photodynamic Transurethral Resection of the Bladder (TUR-B) In Clinical Practice

NCT ID: NCT02012036

Last Updated: 2019-08-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to assess additional detection of Non-Muscle-Invasive Bladder Cancer (NMIBC) with hexyl aminolevulinate (HAL) cystoscopy based on lesions in patients undergoing TUR-B compared to white-light cystoscopy under the conditions of daily clinical practice.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Photodynamic Transurethral Resection of the Bladder (TUR-B)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TUR-B

TUR-B in patients suspected to have non-muscle-invasive bladder cancer (NMIBC).

Hexvix

Intervention Type DRUG

As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.

The detection with Hexvix should be in accordance with local Summary of Product Characteristics \[SmPC\].

Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hexvix

As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.

The detection with Hexvix should be in accordance with local Summary of Product Characteristics \[SmPC\].

Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

hexyl aminolevulinate (HAL)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Indication of TURB due to suspicion of NMIBC (patients suspected to have non muscle invasive bladder cancer).
* Subject able to comply with the protocol.
* Written informed consent available.

Exclusion Criteria

* Hypersensitivity to the active substance or to any of the excipients of the solvent.
* Porphyria.
* Gross haematuria.
* Women of child-bearing potential.
* Repeated TURB (control TURB) as part of follow-up after previous TURB.
* Bacillus Calmette-Guerin (BCG) or Mitomycin / intravesical chemotherapy instillation therapy in the last 12 weeks or any other contraindications according to the SmPC.
* Subjects not able to give informed consent.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ipsen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ipsen Medical Director

Role: STUDY_DIRECTOR

Ipsen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Caritas-Krankenhaus St. Josef, Klinik fuer Urologie

Regensburg, , Germany

Site Status

Klinikverbund Südwest

Sindelfingen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A-94-58150-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Chemoablation for Low-Grade Bladder Cancer
NCT07019220 RECRUITING PHASE2